Article Information
History
- June 20, 2022.
Article Versions
- Version 1 (May 1, 2022 - 10:38).
- Version 2 (May 3, 2022 - 09:56).
- You are currently viewing Version 3 of this article (June 20, 2022 - 05:07).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Wei-Kai Hua1,*,
- Jeff C. Hsu1,*,
- Yi-Chun Chen1,*,
- Peter S. Chang1,
- Kuo-Lan Karen Wen1,
- Po-Nan Wang2,
- Yi-Shan Yu1,
- Ying-Chun Chen1,
- I-Cheng Cheng1 and
- Sareina Chiung-Yuan Wu1,†
- 1GenomeFrontier Therapeutics, Inc. Taipei City, Taiwan (R.O.C.)
- 2Division of Hematology, Chang Gung Medical Foundation, Linkou Branch, Taipei City, Taiwan (R.O.C.)
- ↵†Correspondence should be addressed to: S.C.-Y.W. (sareina{at}genomefrontier.com) 18F-1, No. 3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C.); +886-2-26558766;
↵* These authors contributed equally to this work and their authorship order is interchangeable